Maria T. Rojeski - Publications

Romosozumab reduces incidence of new vertebral fractures across severity grades among postmenopausal women with osteoporosis.

Journal: Bone

Published: July 30, 2021

Romosozumab Enhances Vertebral Bone Structure in Women With Low Bone Density.

Journal: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research

Published: May 08, 2021

Romosozumab and antiresorptive treatment: the importance of treatment sequence.

Journal: Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA

Published: April 21, 2021

T-Score as an Indicator of Fracture Risk During Treatment With Romosozumab or Alendronate in the ARCH Trial.

Journal: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research

Published: September 23, 2019

A single dose of zoledronate preserves bone mineral density for up to 2 years after a second course of romosozumab.

Journal: Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA

Published: June 11, 2019